gmenuen-01-off sen01 gmenuen-02-off- sen01 gmenuen-03-off sen01 gmenuen-04-off sen01 gmenuen-05-off- sen01 gmenuen-06-off
Home R&D

From Prevention to Treatment, Utilizing the Latest Biotechnology

rd12 Regardless of the field, the expectation for technological innovation is ever present. Kaketsuken has been conducting advanced research to comply with the demands of the time, by utilizing its ever evolving biosis engineering technology, i.e. biotechnology, and its superior core knowledge of immunology, microbiology, hematology, veterinary science and biochemistry. In order to respond to diverse medical needs, Kaketsuken is always striving to create new technology and was among the first to work on techniques for genetic recombination and cell fusion technology. Through large-scale culturing and purification of recombinant yeast, Kaketsuken developed the first recombinant Hepatitis B vaccine ("Bimmugen") in Japan, which is one of its numerous accomplishments to date.

Kaketsuken's Biotechnology

Antibody Production Technology for Treatment
Humanized mouse antibody technology
Complete Human phage antibody library
Therapeutic Antibodies/Protein Engineering
(Utilizing Molecular Evolution & Molecular Modeling)
Improving antibody affinity & specificity
Improving protein stability
Recombinant Vector Vaccines
Human vector vaccine manufacturing technology
Veterinary vector vaccine manufacturing technology
High Expression and Production of Recombinant Proteins
Technology of high expression and mass culture for E coli and yeasts
High expression technology for animal cells (the expression of CAG)
High density culturing technology for animal cells
High purification technology for proteins


The development of Kaketsuken's antibody products had its beginnings in cell fusion technology, where the first humanized mouse antibody technology in Japan was introduced from the Medical Research Council in the UK. This gave a clear view of the clinical application of such mouse antibody technology.

Utilizing this technology, a clinical trial is being conducted in the US for an anti-HIV humanized monoclonal antibody (AIDS drug) which was confirmed in a pre-clinical trial to be effective in the prevention of HIV infection. Furthermore, Kaketsuken introduced a widely-applicable phage antibody library from XOMA Company in the US, with the aim of developing pharmaceutical antibody products using human antibody manufacturing technology.

Also, the aforementioned recombinant yeast technology has been used for mass production of recombinant human serum albumin. Furthermore, Kaketsuken is currently evolving towards establishing large scale culturing and purification technology of animal cells in addition to microorganisms. At present, Kaketsuken has been maintaining production capabilities which can address any stages necessary for bio-pharmaceutical development, from lab scale to mass production or production of an investigational new drug.

Thus, "Manufacturing" is our strength. However, Kaketsuken's true strength lies in its adeptness at protein technology. Without such technology, our expertise in recombinant and culturing technology could not be sufficiently put to use.

Main Development Targets


rd11 Utilizing our expertise, Kaketsuken has been working on the application for therapeutic products such as immune disorders, hematological diseases and other rare diseases. For instance, Kaketsuken led the world in identifying and acquiring the patent for the ADAMTS13 gene which is known as a causative gene for thrombotic thrombocytopenic purpura (TTP). By licensing the patent to Baxter Company, Kaketsuken has been contributing to the global development of TTP treatment drugs.

The mapping of the human genome has been completed. However, this does not mean that we know all there is to know about the biological phenomena. It is still necessary to identify the functions of proteins which have genetically expressed materials.

Kaketsuken will apply the biotechnology, such as protein handling technology and genetic engineering technology, which have been accumulated to date, and continue to work on the development of leading technology and new drugs within our fields of expertise, in order to "harness biological substances for preventing and treating more diseases".